Wei Zhi-Jian, Qiao Ya-Ting, Zhou Bai-Chuan, Rankine Abigail N, Zhang Li-Xiang, Su Ye-Zhou, Xu A-Man, Han Wen-Xiu, Luo Pan-Quan
Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, China.
Department of Gastrointestinal Surgery, Affiliated Hospital of HeBei University, Baoding 071000, Hebei Province, China.
World J Gastrointest Surg. 2022 Aug 27;14(8):788-798. doi: 10.4240/wjgs.v14.i8.788.
In recent years, the incidence of types II and III adenocarcinoma of the esophagogastric junction (AEG) has shown an obvious upward trend worldwide. The prognostic prediction after radical resection of AEG has not been well established.
To establish a prognostic model for AEG (types II and III) based on routine markers.
A total of 355 patients who underwent curative AEG at The First Affiliated Hospital of Anhui Medical University from January 2014 to June 2015 were retrospectively included in this study. Univariate and multivariate analyses were performed to identify the independent risk factors. A nomogram was constructed based on Cox proportional hazards models. The new score models was analyzed by C index and calibration curves. The receiver operating characteristic (ROC) curve was used to compare the predictive accuracy of the scoring system and tumor-node-metastasis (TNM) stage. Overall survival was calculated using the Kaplan-Meier curve amongst different risk AEG patients.
Multivariate analysis showed that TNM stage (hazard ratio [HR] = 2.286, 0.008), neutrophil-to-lymphocyte ratio (HR = 2.979, 0.001), and body mass index (HR = 0.626, 0.026) were independent prognostic factors. The new scoring system had a higher concordance index (0.697), and the calibration curves of the nomogram were reliable. The area under the ROC curve of the new score model (3-year: 0.725, 95% confidence interval [CI] 0.676-0.777; 5-year: 0.758, 95%CI 0.708-0.807) was larger than that of TNM staging (3-year: 0.630, 95%CI 0.585-0.684; 5-year: 0.665 95%CI 0.616-0.715).
Based on the serum markers and other clinical indicators, we have developed a precise model to predict the prognosis of patients with AEG (types II and III). The new prognostic nomogram could effectively enhance the predictive value of the TNM staging system. This scoring system can be advantageous and helpful for surgeons and patients.
近年来,食管胃交界部(AEG)Ⅱ型和Ⅲ型腺癌的发病率在全球范围内呈明显上升趋势。AEG根治性切除术后的预后预测尚未完全确立。
基于常规标志物建立AEG(Ⅱ型和Ⅲ型)的预后模型。
回顾性纳入2014年1月至2015年6月在安徽医科大学第一附属医院接受AEG根治术的355例患者。进行单因素和多因素分析以确定独立危险因素。基于Cox比例风险模型构建列线图。通过C指数和校准曲线分析新的评分模型。采用受试者工作特征(ROC)曲线比较评分系统和肿瘤-淋巴结-转移(TNM)分期的预测准确性。使用Kaplan-Meier曲线计算不同风险AEG患者的总生存期。
多因素分析显示,TNM分期(风险比[HR]=2.286,P=0.008)、中性粒细胞与淋巴细胞比值(HR=2.979,P=0.001)和体重指数(HR=0.626,P=0.026)是独立的预后因素。新的评分系统具有更高的一致性指数(0.697),列线图的校准曲线可靠。新评分模型的ROC曲线下面积(3年:0.725,95%置信区间[CI]0.676-0.777;5年:0.758,95%CI 0.708-0.807)大于TNM分期(3年:0.630,95%CI 0.585-0.684;5年:0.665,95%CI 0.616-0.715)。
基于血清标志物和其他临床指标,我们开发了一种精确模型来预测AEG(Ⅱ型和Ⅲ型)患者的预后。新的预后列线图可有效提高TNM分期系统的预测价值。该评分系统对外科医生和患者具有优势且有帮助。